Roth Capital affirmed Cytori Therapeutics (Nasdaq: CYTX) at Buy with a price target of $6 after the company announced preliminary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE